drugset / Trial / NCT06302608
Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy
Phase 0
Active not recruiting
6 enrolled
Xiamen Ophthalmology Center Affiliated to Xiamen University
Non-randomizedSequentialOpen-labelTreatment
Summary
Evaluate the safety and tolerability of NGGT001 subretinal injection for the treatment of crystalline retinal degeneration (BCD)
Timeline
- Start
- 2023-02-08
- Primary completion
- 2024-05-29
- Completion
- 2028-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NGGT001 | Gene therapy (AAV / viral vector) | 1.5e+11 vg | Other |
| Subject | NGGT001 | Gene therapy (AAV / viral vector) | 3e+11 vg | Other |